Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.

"Disclosures Dr. Choy has served on advisory boards and speakers bureau for Eli Lilly and Boehringer Ingelheim. Dr. Mease has received grants/research support from Eli Lilly and Company, Pfizer, Inc, Cypress Bioscience, Forest, Allergan, Fralex, and Boehringer Ingelheim; he has been a consultant for Eli Lilly and Company, Pfizer, Inc, Cypress Bioscience, Forest, Allergan, Fralex, Boehringer Ingelheim, Pierre Fabre, and Wyeth; and he is on the Speakers Bureau of Pfizer, Inc. Drs. Kajdasz, Wohlreich, Walker, and Chappell are or were employees of Eli Lilly. Dr. Crits-Christoph has received income from Eli Lilly, Pfizer, Cephalon, Sepracor, and Alkermes."

"The authors thank the many clinical investigators who participated in the five studies included in this article. The authors also wish to thank Wei J. Chen, MS, Steve Gelwicks, MS, Indu Lakhani, MS, and Christine M. Young (i3Statprobe) for their assistance with the statistical analyses presented herein. The studies presented here were funded by Eli Lilly and Company and Boehringer Ingelheim GmbH."